Just a reminder that we are over 40 months past the time **median enrollment was met. (aka: or about **165 patients.).
We are about 25.5 months since last surgery/screening.
We are at about 22.5 months since last enrollment.
The trial is pragmatically about 5.5 years old and literally almost ten years old.
There are likely approximately 95 to 99 (29% +) patients still alive, imho.
There are likely still over 70 patients that have not progressed, imho. If all estimated 71+ not progressed are from the treatment group, that would be about one-third or more after all this time.
This trial excluded long lived psPD from the main trial. This likely means they excluded many long lived methylated MGMT. IMHO.
IMHO, the trial has a long tail for:
1. ITT OS -- probable treatment arm.
2. Treatment arm for PFS.
PFS is mature, imho.
This is all in my humble opinion
Market Data 
Markets 
AI
